N-Acetyl Selank Amidate.
N-Acetyl Selank Amidate is a synthetically modified analogue of Selank, carrying N-terminal acetylation and C-terminal amidation that enhance enzymatic stability, improve blood-brain barrier penetration, and extend biological activity compared to the unmodified parent compound.
Want the full narrative? Read the N-Acetyl Selank Amidate Research Guide for the published-study discussion and mechanism deep-dive.
- Key Signals
- Anxiety · Cognition · Immunity
- Origin
- Synthetic (modified Selank analogue)
- Investigator
- Seredenin et al. (RAS), 1990s
- Class
- N-acetylated, C-amidated heptapeptide
- Status (UAE)
- Research compound (off-label)
Selank's Architecture, Engineered to Last
Selank, the parent heptapeptide, is developed from tuftsin at the Russian Academy of Sciences in the 1990s as an anxiolytic without sedation.
N-terminal acetylation and C-terminal amidation produce a more metabolically stable analogue with enhanced blood-brain barrier penetration.
The modified form attracts research interest where greater CNS bioavailability and longer action than unmodified Selank are required.
Seven residues, two key modifications.
Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂
C₃₅H₆₀N₁₂O₉ · MW 792.9 Da
The N-terminal acetyl group and C-terminal amide protect against exopeptidase cleavage — the primary modifications over Selank — yielding a more CNS-penetrant, metabolically stable analogue at 792.9 Da.
Mechanism inherited, independent data absent.
Mechanism inherited from Selank; independent clinical data for this specific modification is absent.
- Anxiolysis without sedation (parent)
- BDNF upregulation confirmed
- Enkephalinase inhibition shown
- Phagocyte activation (tuftsin legacy)
- Enhanced stability vs parent compound
- HAM-A scores reduced (Selank trials)
- No sedation or dependence observed
- Cognitive performance improved
- No independent trials for this analogue
- Longer action than unmodified Selank
- Superior BBB penetration (proposed)
- Enhanced nootropic ceiling
- Depression and PTSD adjunct potential
Sign in to view the full research brief.
Mechanism deep-dive and research dosing protocols — available to registered researchers. It's free and takes under a minute.
No Approval, Not Even Via the Parent
In the UAE, research-grade peptides occupy a defined regulatory category distinct from licensed medicines. Compounds sold under this classification — including those offered by Dubai Peptides — are intended exclusively for qualified research applications, not for human administration.
N-Acetyl Selank Amidate has no regulatory approval in any jurisdiction — including Russia, where existing approval covers only the unmodified Selank nasal spray formulation, a chemically distinct product. No IND or equivalent filing has been submitted for this modified analogue in the US, EU, or UAE. Its terminal acetyl and amidate modifications make it a separate compound from any approved parent.
Seredenin's group synthesises Selank from tuftsin at the Russian Academy, establishing the anxiolytic heptapeptide scaffold this analogue builds on.
Terminal acetylation and amidation are applied to the Selank backbone, producing an analogue with enhanced enzymatic resistance and CNS bioavailability.
N-Acetyl Selank Amidate enters the research-peptide market as a distinct, unapproved compound — no regulatory body has reviewed it independently.